Figure 1 - available via license: Creative Commons Attribution 4.0 International
Content may be subject to copyright.
SEM images of Fe 3 O 4 -PEI (left) and Fe 3 O 4 -PEI-DOX (right) (bar ¼ 500 nm). SEM: scanning electron microscope; PEI: polyetherimide; DOX: doxorubicin.
Source publication
To solve the problem of tumor multidrug resistance in cancer therapy, a new drug delivery system of genipin-cross-linked iron (III) oxide/polyetherimide nanoparticles was used to load doxorubicin and small interfering RNA for combined cancer therapy. The results showed that the drug loading and encapsulation efficiency of doxorubicin could reach 45...
Context in source publication
Citations
... The chitosan-functionalized iron-oxide nanoparticles loaded with doxorubicin was targeted towards ovarian cancer cell (SK-Ov-3) for targeted therapy (Adimoolam et al., 2018). Similarly, Genipin-cross-linked iron (III) oxide/polyetherimide nanoparticles are loaded with doxorubicin is used in cancer therapy targeting HeLa cells (Long et al., 2017), iron-oxide NPs coated with poly(N-isopropyl acrylamide) is loaded with doxorubicin and targeted towards cervical cancer cells for theranostic applications (Yar et al., 2018), and the folic acid conjugated PEG-coated MNPs are loaded with doxorubicin and targeted towards HeLa cells to bring efficient anticancer activity in minimal dose (Erdem et al., 2017). ...
Conventional cancer treatment techniques show several limitations including low or no specificity and consequently a low efficacy in discriminating between cancer cells and healthy cells. Recent nanotechnology developments have introduced smart and novel therapeutic nanomaterials that take advantage of various targeting approaches. The use of nanotechnology in medicine and, more specifically, drug delivery is set to spread even more rapidly than it has over the past two decades. Currently, many nanoparticles (NPs) are under investigation for drug delivery including those for cancer therapy. Targeted nanomaterials bind selectively to cancer cells and greatly affect them with only a minor effect on healthy cells. Gold nanoparticles (Au-NPs), specifically, have been identified as significant candidates for new cancer therapeutic modalities because of their biocompatibility, easy functionalization and fabrication, optical tunable characteristics, and chemophysical stability. In the last decade, there has been significant research on Au-NPs and their biomedical applications. Functionalized Au-NPs represent highly attractive and promising candidates for drug delivery, owing to their unique dimensions, tunable surface functionalities, and controllable drug release. Further, iron oxide NPs due to their “superparamagnetic” properties have been studied and have demonstrated successful employment in numerous applications. In targeted drug delivery systems, drug-loaded iron oxide NPs can accumulate at the tumor site with the aid of an external magnetic field. This can lead to incremental effectiveness in drug release to the tumor site and vanquish cancer cells without harming healthy cells. In order for the application of iron oxide NPs in the human body to be realized, they should be biodegradable and biocompatible to minimize toxicity. This review illustrates recent advances in the field drug and small molecule delivery such as fluorouracil, folic acid, doxorubicin, paclitaxel, and daunorubicin, specifically when using gold and iron oxide NPs as carriers of anticancer therapeutic agents.
